Does Clinical Treatment with Phenylbutazone and Meloxicam in the Pre‐ovulatory Period Influence the Ovulation Rate in Mares?

• Published in: Reproduction in domestic animals 2015-10, Vol.50 (5), p.771-775
• Main Authors: Lima, AG, Costa, LCB, Alvarenga, MA, Martins, CB
• Format: Article
• Language: English
• Subjects: Animals; anovulation; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage; conception; economic impact; Estrous Cycle; Female; Follicular Phase; hemorrhage; Horses - physiology; luteinization; Luteinization - drug effects; Male; mares; meloxicam; nonsteroidal anti-inflammatory agents; Ovarian Follicle - diagnostic imaging; Ovulation - drug effects; Ovulation Induction - veterinary; phenylbutazone; Phenylbutazone - administration & dosage; Pregnancy; prostaglandins; Thiazines - administration & dosage; Thiazoles - administration & dosage; Triptorelin Pamoate - administration & dosage; Triptorelin Pamoate - analogs & derivatives; ultrasonics; Ultrasonography
• ISSN: 0936-6768; 1439-0531
• DOI: 10.1111/rda.12586

The presence of anovulatory haemorrhagic follicles during the oestrous cycle of mares causes financial impacts, slowing conception and increasing the number of services per pregnancy. Non‐steroidal anti‐inflammatory drugs (NSAIDs) such as meloxicam and phenylbutazone are used in the treatment of several disorders in mares, and these drugs can impair the formation of prostaglandins (PGs) and consequently interfere with reproductive activity. This study aimed to evaluate the effects of treatment with NSAIDs on the development of pre‐ovulatory follicles in mares. In total, 11 mares were studied over three consecutive oestrous cycles, and gynaecological and ultrasound examinations were performed every 12 h. When 32‐mm‐diameter follicles were detected, 1 mg of deslorelin was administered to induce ovulation. The first cycle was used as a control, and the mares received only a dose of deslorelin. In the subsequent cycles, in addition to receiving the same dose of deslorelin, each mare was treated with NSAIDs. In the second cycle, 4.4 mg/kg of phenylbutazone was administered, and in the third cycle, 0.6 mg/kg of meloxicam was administered once a day until ovulation or the beginning of follicular haemorrhage. All of the mares ovulated between 36 and 48 h after the induction in the control cycle. In the meloxicam cycle, 10 mares (92%) did not ovulate, while in the phenylbutazone cycle, nine mares (83%) did not ovulate. In both treatments, intrafollicular hyperechoic spots indicative of haemorrhagic follicles were observed on ultrasound. Thus, our results suggested that treatment with meloxicam and phenylbutazone at therapeutic doses induced intrafollicular haemorrhage and luteinization of anovulatory follicles.